COVID-19 Vaccination Uptake and Hesitancy Among Current Tobacco Users
- PMID: 34987300
- PMCID: PMC8721404
- DOI: 10.1177/1179173X211068027
COVID-19 Vaccination Uptake and Hesitancy Among Current Tobacco Users
Abstract
Novel mRNA vaccines have been developed and were first distributed to high-risk individuals (including smokers) in the United States starting in December 2020 to combat the coronavirus (COVID-19) pandemic. Over one-half of the U.S. adult population has received at least 1 dose of a COVID-19 vaccine, but many others have reported hesitation about becoming vaccinated. We examined COVID-19 vaccine uptake and hesitancy from a convenience sample of Pennsylvanian adult smokers in April 2021, approximately 3 months after tobacco users were eligible to receive vaccination in the state. Participants (n = 231) were 23.4% male, 90.5% white, and had a mean age of 48.1 (SD = 11.9) years. All participants were current tobacco users, with the majority reporting current cigarette smoking (90.9%) with an average of 16 (SD = 8.1) cigarettes smoked per day. Nearly 60% (n = 137) reported receiving at least 1 dose of the vaccine and of those who did not (n = 94), 84% (n = 79) said they were somewhat or very unlikely to get a vaccine. Those who were unvaccinated were more likely to not consume news about COVID-19 (chi-square P-value < .01) and less likely to believe government news sources as reliable information for COVID-19 (chi-square P-value < .01). Qualitative responses among those who were vaccine hesitant expressed concerns about the lack of research on the vaccine, distrust of the safety of the vaccine, and fears about side effects. Understanding vaccine hesitancy among tobacco users can help develop targeted communication strategies and directly address concerns to promote vaccination among this population who may be at an increased risk of severe complications from COVID-19.
Keywords: COVID-19; hesitancy; smoking; tobacco; vaccination.
© The Author(s) 2021.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: J.F. has done paid consulting for Pfizer regarding smoking cessation medications. The other authors have no disclosures to report related to this publication.
References
-
- Johns Hopkins University . Coronavirus Resource Center. https://coronavirus.jhu.edu/. https://coronavirus.jhu.edu/. Accessed June 20, 2021.
-
- Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
